ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v9i3.315ppharm-319Research ArticleВАКЦИНАЦИЯ В СОВРЕМЕННОМ МИРЕVACCINATIONНОВЫЕ ДАННЫЕ ПО ЭФФЕКТИВНОСТИ 13-ВАЛЕНТНОЙ ПНЕВМОКОККОВОЙ КОНЪЮГИРОВАННОЙ ВАКЦИНЫ В ОТНОШЕНИИ ИНВАЗИВНЫХ ПНЕВМОКОККОВЫХ ИНФЕКЦИЙ, ПНЕВМОНИЙ, ОСТРОГО СРЕДНЕГО ОТИТА И НАЗОФАРИНГЕАЛЬНОГО НОСИТЕЛЬСТВАEFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGEРайнертРальф РенеReinertRalf Rene
директор по научным направлениям
ralfrene.reinert@pfizer.comТайшиБулентTaysiBulentneonatepearl@yandex.ruPfizer H.C.P. Corporation, Колледжвилль, СШАСоединённые Штаты АмерикиPfizer Vaccines, Collegeville, USAUnited States20121506201293Педиатрическая фармакология811Copyright © Райнерт Р., Тайши Б., 20122012Райнерт Р., Тайши Б.Reinert R., Taysi B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/319пневмококковая инфекциясеротипы пневмококковпрофилактикапневмококковая конъюгированная вакцинадети.pneumococcal diseasepneumococcal serotypespreventionpneumococcal conjugate vaccinechildrenReferencesWHO. Pneumococcal conjugate vaccine for childhood immunization? WHO position paper. Wkly Epidemiol Rec. 2007; 82 (12): 93-104.WHO. Pneumococcal conjugate vaccine for childhood immunization? WHO position paper. Wkly Epidemiol Rec. 2007; 82 (12): 93-104.O'Brien K.L., Wolfson L.J., Watt J.P. et al. Burden of disease caused by streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009; 374 (9693): 893-902.O'Brien K.L., Wolfson L.J., Watt J.P. et al. Burden of disease caused by streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009; 374 (9693): 893-902.Musher D.M. Infections caused by streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity and treatment. Clinical Infectious Diseases. 1992; 14 (4): 801-807.Musher D.M. Infections caused by streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity and treatment. Clinical Infectious Diseases. 1992; 14 (4): 801-807.WHO. Pneumococcal vaccines ? WHO position paper – 2012. Wkly Epidemiol Rec. 2012; 14: 129–144.WHO. Pneumococcal vaccines ? WHO position paper – 2012. Wkly Epidemiol Rec. 2012; 14: 129–144.Reinert R.R., Paradiso P., Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines. 2010; 9 (3): 229-236.Reinert R.R., Paradiso P., Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines. 2010; 9 (3): 229-236.Paradiso P.R. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis. 2010; 52 (10): 1241-1247.Paradiso P.R. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis. 2010; 52 (10): 1241-1247.FDA. 2010. [cited; Available from]. URL: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201741.htmFDA. 2010. [cited; Available from]. URL: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201741.htmWHO. Pneumococcal conjugate vaccines: recommendations for the production and control of pneumococcal conjugate vaccines WHO Technical report series, No. 927, Annex 2. 2005. [cited; Available from]. URL: http://www.who.int/biologicals/publications/trs/areas/vaccines/pneumo/en/index.htmlWHO. Pneumococcal conjugate vaccines: recommendations for the production and control of pneumococcal conjugate vaccines WHO Technical report series, No. 927, Annex 2. 2005. [cited; Available from]. URL: http://www.who.int/biologicals/publications/trs/areas/vaccines/pneumo/en/index.htmlFeavers I., Knezevic I., Powell M., Griffiths E. Challenges in the evaluation and licensing of new pneumococcal vaccines. 7-8 July 2008, Ottawa, Canada. Vaccine. 2009; 27 (28): 3681-3688.Feavers I., Knezevic I., Powell M., Griffiths E. Challenges in the evaluation and licensing of new pneumococcal vaccines. 7-8 July 2008, Ottawa, Canada. Vaccine. 2009; 27 (28): 3681-3688.Isaacman D.J., McIntosh E.D., Reinert R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010; 14 (3): 197-209.Isaacman D.J., McIntosh E.D., Reinert R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010; 14 (3): 197-209.Pilishvili T., Lexau C., Farley M.M. et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010; 201 (1): 32-41.Pilishvili T., Lexau C., Farley M.M. et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010; 201 (1): 32-41.Reinert R., Jacobs M.R., Kaplan S.L. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010; 28 (26): 4249-4259.Reinert R., Jacobs M.R., Kaplan S.L. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010; 28 (26): 4249-4259.McIntosh E.D., Reinert R.R. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines. 2010; 10 (1): 109-129.McIntosh E.D., Reinert R.R. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines. 2010; 10 (1): 109-129.Jauneikaite E., Jefferies J.M., Hibberd M.L., Clarke S.C. Prevalence of streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: A review. Vaccine. 2012 Apr 1.Jauneikaite E., Jefferies J.M., Hibberd M.L., Clarke S.C. Prevalence of streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: A review. Vaccine. 2012 Apr 1.Johnson H.L., Deloria-Knoll M., Levine O.S. et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010; 7 (10).Johnson H.L., Deloria-Knoll M., Levine O.S. et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010; 7 (10).Fitzwater S.P., Chandran A., Santosham M., Johnson H.L. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012; 31 (5): 501-508.Fitzwater S.P., Chandran A., Santosham M., Johnson H.L. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012; 31 (5): 501-508.Schuchat A., Bell P.B. Monitoring the impact of vaccines postlicensure: new challenges: role of surveillance in evaluating vaccine performance. Medscape View Article. 2012. URL: http://www.medscape.com/viewarticle/576711_7Schuchat A., Bell P.B. Monitoring the impact of vaccines postlicensure: new challenges: role of surveillance in evaluating vaccine performance. Medscape View Article. 2012. URL: http://www.medscape.com/viewarticle/576711_7Miller E., Andrews N.J., Waight P.A. et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29 (49): 9127-9131.Miller E., Andrews N.J., Waight P.A. et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29 (49): 9127-9131.Andrews N., Kaye P., Slack M. et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against IPD in England and Wales. International symposium on pneumococci and pneumococcal diseases, ISPPD-8. 11-15 March, 2012. Iguacu Falls, Brazil. Poster 148. 2012.Andrews N., Kaye P., Slack M. et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against IPD in England and Wales. International symposium on pneumococci and pneumococcal diseases, ISPPD-8. 11-15 March, 2012. Iguacu Falls, Brazil. Poster 148. 2012.Moore M. G1-538. Early impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old, U.S, 2010. 51 ICAAC. Chicago. 2011.Moore M. G1-538. Early impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old, U.S, 2010. 51 ICAAC. Chicago. 2011.Moore M., Link-Gelles R., Farley M. et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), US, 2010-2011. International symposium on pneumococci and pneumococcal diseases, ISPPD-8; 11-15 March 2012. Iguacu Falls, Brazil. Poster 179. 2012.Moore M., Link-Gelles R., Farley M. et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), US, 2010-2011. International symposium on pneumococci and pneumococcal diseases, ISPPD-8; 11-15 March 2012. Iguacu Falls, Brazil. Poster 179. 2012.Cox C.M. Early impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease USA 2010–2011. National immunization conference, March 26 2012. Atlanta, GA. Paper 30196. 2012. URL: http://cdc.confex.com/cdc/nic2012/webprogram/Paper30196.htmlCox C.M. Early impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease USA 2010–2011. National immunization conference, March 26 2012. Atlanta, GA. Paper 30196. 2012. URL: http://cdc.confex.com/cdc/nic2012/webprogram/Paper30196.htmlVan der Linden M., Imohl M. Epidemiologie invasiver Pneumokokkenerkrankungen bei kindern in Deutschland von 1997-2012: Effekte nach einfuhrung der pneumokokken-konjugatimpfung. Jahrestagung der Deutschen gesellschaft fur padiatrische infektiologie (DGPI). 19.04.-21.04.2012. Mannheim, Germany. Poster. 2012.Van der Linden M., Imohl M. Epidemiologie invasiver Pneumokokkenerkrankungen bei kindern in Deutschland von 1997-2012: Effekte nach einfuhrung der pneumokokken-konjugatimpfung. Jahrestagung der Deutschen gesellschaft fur padiatrische infektiologie (DGPI). 19.04.-21.04.2012. Mannheim, Germany. Poster. 2012.Picazo J., Ruiz-Contreras J., Casado-Flores J. et al. First impact data of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumocococcal disease in children in Madrid, 2010-2011 (HERACLES study). International symposium on pneumococci and pneumococcal diseases, ISPPD-8. 11-15 March 2012. Iguacu Falls, Brazil. Poster 189. 2012.Picazo J., Ruiz-Contreras J., Casado-Flores J. et al. First impact data of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumocococcal disease in children in Madrid, 2010-2011 (HERACLES study). International symposium on pneumococci and pneumococcal diseases, ISPPD-8. 11-15 March 2012. Iguacu Falls, Brazil. Poster 189. 2012.Picazo J., Ruiz-Contreras J., Casado-Flores J. et al. Serotype distribution of invasive pneumocococcal disease cases after the introduction of 13 valent pneumococcal conjugate vaccine (PCV13) in children in Madrid. International symposium on pneumococci and pneumococcal diseases, ISPPD-8. 11-15 March 2012. Iguacu Falls, Brazil. Poster 190. 2012.Picazo J., Ruiz-Contreras J., Casado-Flores J. et al. Serotype distribution of invasive pneumocococcal disease cases after the introduction of 13 valent pneumococcal conjugate vaccine (PCV13) in children in Madrid. International symposium on pneumococci and pneumococcal diseases, ISPPD-8. 11-15 March 2012. Iguacu Falls, Brazil. Poster 190. 2012.Pirez M.C., Algorta G., Cedres A. et al. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J. 2010; 30 (8): 669-674.Pirez M.C., Algorta G., Cedres A. et al. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J. 2010; 30 (8): 669-674.Machado M., Kouyoumdjian G., Marquez S. et al. Complicated pneumonia in children 0-14 years of age after the introduction of pneumococcal conjugated vaccines (PCV7/13) hospital pereira Rossell-Uruguay 1/1/2010-31/9/2011. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11?15, 2012. Iguacu Falls, Brazil. 2012.Machado M., Kouyoumdjian G., Marquez S. et al. Complicated pneumonia in children 0-14 years of age after the introduction of pneumococcal conjugated vaccines (PCV7/13) hospital pereira Rossell-Uruguay 1/1/2010-31/9/2011. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11?15, 2012. Iguacu Falls, Brazil. 2012.Hortal M., Estevan M., Laurani H. et al. Decline in pediatric pneumonia hospitalizations following PCV7 and PCV13 introduction in Uruguay. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11-15, 2012. Iguacu Falls, Brazil. 2012.Hortal M., Estevan M., Laurani H. et al. Decline in pediatric pneumonia hospitalizations following PCV7 and PCV13 introduction in Uruguay. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11-15, 2012. Iguacu Falls, Brazil. 2012.Spencer D. et al. Complicated pneumonia in children. Presented at the 29th annual meeting of the European society of pediatric infectious diseases, June 7-11 2011. The Hague, Netherlands. 2011.Spencer D. et al. Complicated pneumonia in children. Presented at the 29th annual meeting of the European society of pediatric infectious diseases, June 7-11 2011. The Hague, Netherlands. 2011.Pichichero M.C., Casey J.R., Center K. et al. Efficacy of PCV13 in prevention of AOM and NP colonization in children. First year of data from the US. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11-15, 2012. Iguacu Falls, Brazil. 2012.Pichichero M.C., Casey J.R., Center K. et al. Efficacy of PCV13 in prevention of AOM and NP colonization in children. First year of data from the US. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11-15, 2012. Iguacu Falls, Brazil. 2012.Dagan R., Patterson S., Juergens C. et al. The efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13). Additional serotypes on nasopharyngeal colonization: A randomized double-blind pediatric trial. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11-15, 2012. Iguacu Falls, Brazil. 2012.Dagan R., Patterson S., Juergens C. et al. The efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13). Additional serotypes on nasopharyngeal colonization: A randomized double-blind pediatric trial. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11-15, 2012. Iguacu Falls, Brazil. 2012.Cohen R., Levy C., Bingen E. et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012; 31 (3): 297-301.Cohen R., Levy C., Bingen E. et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012; 31 (3): 297-301.
The authors declare that there are no conflicts of interest present.